Johnson Controls Intl (NYSE:JCI) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.49 by 6.12 percent. This is a 23.81 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $5.59 billion which missed the analyst consensus estimate of $5.60 billion by 0.11 percent. This is a 2.76 percent increase over sales of $5.44 billion the same period last year.
Can Ketamine For Depression Be Improved? New Study Will Look Into Ketamine Analog Arketamine
Perception Neuroscience, an Atai Life Sciences (NASDAQ: ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate.
